Clinical trials · New York
Leukemia clinical trials in New York
We’re tracking 178 recruiting leukemia studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT03739814RecruitingPhase 2
Test inotuzumab, blinatumomab, and possibly ponatinib for CD22 ALL
This Phase 2 study tests a combination of medicines (inotuzumab ozogamicin and blinatumomab), with or without ponatinib, for people with CD22-positive B-cell acute lymphoblastic leukemia (ALL). It aims to improve remission and control leukemia cells, including in the bone marrow.
Buffalo, New YorkAges 18 years+ - NCT07661095RecruitingPhase 1
Study of CRD3874-SI for relapsed or refractory AML
This trial tests a new drug, CRD3874-SI, for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The goal is to see if this drug can help control the leukemia.
Rockville Centre, New YorkAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
New York, New YorkAges 1–21 - NCT07566377RecruitingPhase 2
Cord Blood Transplant for Children and Young Adults With Blood Cancer
This study tests whether using cord blood stem cells (collected from umbilical cords after birth) can help treat high-risk blood cancers in children and young adults when a matched donor is not quickly available. Cord blood transplants may help prevent cancer from coming back.
New York, New YorkAges Up to 26 years - NCT05190471RecruitingPhase 1
Study drug for adults with AML that did not respond or returned
This Phase 1 study tests BP1002 in adults with acute myeloid leukemia (AML) that is refractory (not responding) or relapsed (coming back). It’s early-stage, aiming to find a safe dose and see if the treatment can help people with limited options.
New York, New YorkAges 18 years+ - NCT07216443RecruitingPhase 2
Study of orca-t for leukemia or MDS with reduced intensity chemo
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
New York, New YorkAges 18 years+ - NCT07061951RecruitingPhase 2
Mirdametinib for relapsed or refractory CLL or SLL
This trial tests a drug called mirdametinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments, including a BTK inhibitor and a BCL2 inhibitor. The goal is to see if mirdametinib can help shrink the cancer or slow its growth.
New York, New YorkAges 18 years+ - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Albany, New YorkAges 1–25 - NCT07011004RecruitingPhase 1
NK cells plus atezolizumab for acute myeloid leukemia
This trial tests combining natural killer (NK) immune cells with an immunotherapy drug (atezolizumab) for people with acute myeloid leukemia (AML) that didn't respond to or came back after prior treatments. It aims to see if this combination can help the body fight the leukemia.
Rockville Centre, New YorkAges 18–70 - NCT06871410RecruitingPhase 1
Engineered immune cells for relapsed or refractory AML
This trial tests a new type of cell therapy called CD83 CAR T cells for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. These cells are designed to find and attack the leukemia cells while sparing healthy cells.
Buffalo, New YorkAges 18 years+ - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
New York, New YorkAges 18 years+ - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Valhalla, New YorkAges 18 years+ - NCT06773936Enrolling by invitationPhase 2
Adding asciminib to usual care for adults with newly diagnosed Ph+ ALL
This trial tests if adding asciminib, a targeted pill, to standard treatment works better for adults newly diagnosed with a specific type of acute lymphoblastic leukemia (Ph+ ALL). It is for those who are older, or who cannot or choose not to have intensive chemotherapy.
Lake Success, New YorkAges 60 years+ - NCT05237258Recruiting
Compare palliative care approaches for people with high-risk AML
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
Rochester, New YorkAges 18–120 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Valhalla, New YorkAges 13–90 - NCT06317662RecruitingPhase 2
Adding venetoclax and blinatumomab to chemo for infant leukemia
This trial tests adding two newer medicines (venetoclax and blinatumomab) to standard chemotherapy for infants with a specific type of leukemia. The goal is to see if this combination helps more babies stay cancer-free.
Albany, New YorkAges Up to 12 months - NCT06297551Recruiting
Study of leukemia stem cell markers in AML
This trial looks at two markers, CLL1 and CD45RA, found on some leukemia cells. It aims to help doctors better understand and treat acute myeloid leukemia (AML) by measuring these markers at diagnosis.
Stony Brook, New YorkAges 18 years+ - NCT06207123RecruitingPhase 1/Phase 2
New drug combo for T-cell leukemia or lymphoma
This trial tests a new combination of drugs (LP-118, ponatinib, vincristine, and dexamethasone) for people with T-cell leukemia or lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination can help control the disease.
Rochester, New YorkAges 18 years+ - NCT03595917RecruitingPhase 1
New and hard-to-treat BCR-ABL leukemia drugs plus prednisone and blinatumomab
This Phase 1 study tests a combination of targeted cancer drugs with prednisone and blinatumomab in people with BCR-ABL–positive B-cell leukemia (B-ALL), or chronic myeloid leukemia (CML) in lymphoid blast crisis. It may help by attacking leukemia cells through multiple pathways, especially when standard intensive chemotherapy is not suitable.
Buffalo, New YorkAges 18 years+ - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Uniondale, New YorkAges Any age - NCT05884333RecruitingPhase 2
Cord blood transplant for adults with blood cancer
This Phase 2 study tests using donated cord blood to treat certain adult blood cancers that are at high risk of coming back. It may help strengthen the body’s ability to rebuild blood and fight the cancer after intensive treatment.
New York, New YorkAges 21–65 - NCT05873712RecruitingPhase 2
Zanubrutinib plus CAR-T for Richter syndrome
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
New York, New YorkAges 18 years+ - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
New York, New YorkAges 1 month–21 years - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New York, New YorkAges 18 years+
Leukemia trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting leukemia studies listed above.
- Memorial Sloan Kettering Cancer Center · 9 studies
- Roswell Park Comprehensive Cancer Center · 6 studies
- Weill Cornell Medicine · 4 studies
- Memorial Sloan Kettering Nassau · 3 studies
- Montefiore Medical Center · 3 studies
- University of Rochester · 3 studies
- Albany Medical Center · 2 studies
- Memorial Sloan Kettering Westchester · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Leukemia trials in other states
Common questions
- Are there leukemia clinical trials in New York?
- Yes. We're currently tracking 178 recruiting leukemia studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.